Search results

Filter

Filetype

Your search for "*" yielded 533303 hits

Degree projects

Welcome to do your Degree project at Computational ChemistrySeveral experienced research group leaders can supervise your project, on master’s level or bachelor’s level You can click on the name of a supervisor in the list below, to get to each supervisor’s web page where you can for example read a short comment about what the research group is working with, read a recent publication from that gro

https://www.compchem.lu.se/education/degree-projects - 2025-07-21

Contact

Addresses Visiting addressKemicentrumNaturvetarvägen 22, LundDelivery addressKemicentrumNaturvetarvägen 24, LundPostal addressLund University P.O. Box 124SE-221 00 Lund, SwedenInternal mailHämtställe 1 Directions Directions to the division on Kemicentrum’s website Management Head of DivisionJan Forsmanjan [dot] forsman [at] compchem [dot] lu [dot] se (jan[dot]forsman[at]compchem[dot]lu[dot]se)+46

https://www.compchem.lu.se/contact - 2025-07-21

Start

Research The Division of Computational Chemistry has internationally leading research by research groups with broad ranges of research areas Education The Division of Computational Chemistry has a unique strength and breadth with courses on Bachelor, Master and PhD level Infrastructure Computational Chemistry provide the researchers at LU with a facility where it is possible to measure and simulat

https://www.compchem.lu.se/start - 2025-07-21

Research

Biomolecular AssemblyUsing a range of computational tools including Monte Carlo and Molecular Dynamics simulations we investigate interactions within and between bio-molecules. Examples are protein-protein assembly, protein ionization and pKa values, peptide-membrane interactions. We also develop software for coarse grained protein simulations.Quantum chemistry software and methodologyMolecules ca

https://www.compchem.lu.se/research - 2025-07-21

Infrastructure

Computational Chemistry promotes the usage of X-ray and neutron scattering techniques and provides the researchers at LU with a facility where it is possible to measure and simulate macromolecules in solution and serve as an entry environment to the large scale infrastructures. Computational Cehmistry also promotes software for classical molecular simulations, multireference quantum chemistry calc

https://www.compchem.lu.se/infrastructure - 2025-07-21

Software

Faunus Faunus is a free, object oriented library for classical molecular simulations written in C++/Python. Besides handling macromolecular solutions in various ensembles such as NVT, μVT, NPT, Faunus also covers more excotic topics such as proton fluctuations, arbitrary parallel tempering and hyperspherical geometry.More information on the Faunus website Molcas MOLCAS is a quantum chemistry softw

https://www.compchem.lu.se/infrastructure/software - 2025-07-21

BioSAXS Instrument

In 2021 Infrastructure Call at Lund University, we were gratefully approved funding from LU Central, the Science Faculty, and the Faculty of Engineering for purchasing a Solution X-ray Scattering Instrument for Life Science and Soft Matter, short-name the BioSAXS. Our vision is to promote the usage of X-ray and neutron scattering techniques and provide the researchers at LU with a facility where i

https://www.compchem.lu.se/infrastructure/biosaxs-instrument - 2025-07-21

Job vacancies

Current vacanciesCurrent job vacancies at the Division of Computational Chemistry (Varbi)To apply for a vacant position, you need an account in Lund University’s recruitment system, Varbi.How to apply for a position (Lund University’s website)

https://www.compchem.lu.se/about/job-vacancies - 2025-07-21

Start

Welcome to CREATE Health Our vision: To contribute with innovative diagnostics and therapeutic solutions not for coming generations but for today's CREATE Health aims to provide individualized and improved therapeutic strategies, based on our ability to determine which patient will benefit from a particular treatment. CREATE Health provides solutions to clinical problems by developing innovative d

https://www.createhealth.lth.se/start - 2025-07-21

Centre Management and Board

Centre Management Sara EkCenter Director, Director CanFastersara [dot] ek [at] immun [dot] lth [dot] se (sara[dot]ek[at]immun[dot]lth[dot]se) Corinna RichterResearch Coordinatorcorinna [dot] richter [at] immun [dot] lth [dot] se (corinna[dot]richter[at]immun[dot]lth[dot]se) Board Carl BorrebaeckChairman of the Boardcarl [dot] borrebaeck [at] immun [dot] lth [dot] se (carl[dot]borrebaeck[at]immun[d

https://www.createhealth.lth.se/about/centre-management-and-board - 2025-07-21

Recruitment

Open positions will be advertised on Lund University's website and on our social media channels.If you are a student and interested in doing a Master's or ExJobb project, please contact the PI of the group of interest directly.

https://www.createhealth.lth.se/about/recruitment - 2025-07-21

Ongoing Collaborations and partners

Links will open on the respective websites.Region SkåneMedicon VillageCHUV in LausanneTMUCI in Tianjin, ChinaOslo Cancer ClusterWorking together is an integral part of CREATE Health’s DNA. We can proudly say that CREATE Health’s researchers are highly engaged in many different collaborations and networks – too many to name all of them here. For detailed information on our researchers’ collaborativ

https://www.createhealth.lth.se/research-and-innovation/ongoing-collaborations-and-partners - 2025-07-21

Spin Outs

CantargiaCantargia AB was founded in 2009/2010 by Thoas Fioretos and Marcus Järås (Lund University), Kjell Sjöström (Innovagen), and by LU Bioscience. The company specializes in antibody-based cancer therapy. After initially focusing on treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC), new antibodies designed for the treatment of autoimmune and inflammatory diseases hav

https://www.createhealth.lth.se/research-and-innovation/spin-outs - 2025-07-21

CanFaster

The Translational Cancer Faster Forward doctoral/postdoctoral programmes (2018-2025). The CanFaster programme is supported by the European Union’s Marie Skłodowska-Curie COFUND programme (Horizon 2020 framework) based on the "Mobility across borders" philosophy. The CanFaster programme has attracted international PhD and Postdoc fellows (ER) with an interest in applied medical research in oncology

https://www.createhealth.lth.se/canfaster - 2025-07-21

Publications

The links below open on the respective publication website.In vivo dendritic cell reprogramming for cancer immunotherapy.Authors: Ascic, E., Catena, X., et al.Publication: Science 386, 6719Year: 2024Digital PCR quantification of ultrahigh ERBB2 copy number identifies poor breast cancer survival after trastuzumab.Authors: Meng, P., Dalal, H., Chen, Y., Brueffer, C., Gladchuk, S., Alcaide, M., ... &

https://www.createhealth.lth.se/canfaster/publications - 2025-07-21

Inducing anti-tumor immunity with in-situ direct reprograming of cancer cells to cDC1s

Immunotherapy has transformed the cancer treatment landscape leading to long-term responses. However, these strategies are effective in a limited number of patients and often lose their efficacy as the tumor progresses. Insufficient antigen presentation mediated by MHC downregulation and exclusion of functional antigen-presenting cells (APCs) from the tumor microenvironment (TME) are critical evas

https://www.createhealth.lth.se/canfaster/ongoing-canfaster-postdoc-projects/inducing-anti-tumor-immunity-situ-direct-reprograming-cancer-cells-cdc1s - 2025-07-21

Next generation immuno-oncological targets for cancer therapy

Immuno-oncological (I-O) treatment methods have revolutionized cancer therapy and tremendous clinical benefits are achieved in some cancer patients. However, today a limited number of I-O drug targets are used and only a fraction of all cancer patients has a therapeutic response. We need to further understand the immune system in cancer in order to develop novel treatment strategies and improve su

https://www.createhealth.lth.se/canfaster/ongoing-canfaster-postdoc-projects/next-generation-immuno-oncological-targets-cancer-therapy - 2025-07-21